ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

587
Analysis
Health Care • China
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
bullish•Wuxi Biologics
•01 Sep 2020 18:25

Wuxi Biologics Placement - Another One Before Lock-Up, but Just in Time for the Index Inclusion

Wuxi Biologics (Cayman) Inc (2269 HK)Ā has seen a total of ten placements since listing in Jun 2017. We've covered all of the deals. Given that the...

Logo
518 Views
Share
•23 Aug 2020 15:21

Hong Kong Connect Weekly: Meituan, Smoore, SMIC, Wuxi Biologics

In our weekly HK Connect Flow series, we aim to highlight key stocks and sectors which the mainland investors traded via the southbound Hong Kong...

Logo
346 Views
Share
bullish•Meituan
•17 Aug 2020 12:37

Hang Seng Index - Possible Changes in Upcoming Reviews

The Hang Seng Indexes Company Limited (HSIL)Ā announced the results of its September review of the Hang Seng Family of Indexes post market close on...

Logo
566 Views
Share
bullish•Wuxi Biologics
•15 Aug 2020 10:42

Hang Seng Index Rebalance - Big Turnover, Big Impact, Some Surprises and More Changes to Come

The Hang Seng Indexes Company Limited (HSIL) announced the results of its review of the Hang Seng Family of Indexes post market close on 14 August....

Logo
1.1k Views
Share
•19 Jul 2020 14:14

ECM Weekly (19 July 2020) - HK IPO Analytics 1H2020, Shimao Services, AyalaLand REIT, Li Auto

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. Hong...

Share
x